KRRO Stock Forecast & Price Target

Korro Bio is supported by a differentiated RNA-editing platform that targets large unmet needs with a precise, transient mechanism, most notably KRRO-121 for hyperammonemia and the GalNAc-conjugated AATD program. The investment case is strengthened by clear clinical success criteria in UCDs, where durable ammonia control below 200 μmol/L is the key bar, and by encouraging ASGCT data showing >70% SERPINA1 editing and about 90% M-AAT protein in vivo with repeat dosing. Financially, the PIPE reset lifted cash and marketable securities to $157.1M at 3/31/26, with an operational runway into 2H28, while the net loss improved to $19.6M from a derived ~$50.0M in 4Q25.

Korro Bio is viewed pessimistically because its valuation is built on a modest $225M EV with only a 20% approval probability for KRRO-121 in UCD and 10% for KRRO-111 in AATD, underscoring fragile fundamental support. The thesis is further weakened by explicit risks of clinical delays, the possibility of unfavorable data from ongoing programs—especially KRRO-121—and the absence of product revenues, leaving value dependent on uncertain pipeline execution. With 20M fully diluted shares outstanding and potential long-term dilution risk, the company’s cash-adjusted upside looks constrained and highly sensitive to development setbacks.